INM
InMed Pharmaceuticals Inc.NASDAQHealthcare$0.68+2.46%ClosedMarket Cap: $1.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.00
P/S
0.24
EV/EBITDA
0.87
DCF Value
$-5.85
FCF Yield
-708.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
26.5%
Operating Margin
-174.6%
Net Margin
-171.6%
ROE
-62.9%
ROA
-59.0%
ROIC
-66.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 2026 | $1.1M | 3.2% | $-2.9M | $-2.8M | $-703.84 | — |
| Q1 2026 | $1.1M | 36.0% | $-1.8M | $-1.7M | $-436.75 | — |
| Q4 2025 | $1.8M | 44.2% | $-2.4M | $-2.4M | $-1.22 | — |
| FY 2025 | $4.9M | 34.5% | $-7.9M | $-8.2M | $-11.44 | — |
| Q3 2025 | $1.3M | 13.9% | $-2.1M | $-2.1M | $-1.94 | — |
| Q2 2025 | $1.1M | 41.5% | $-2.2M | $-2.6M | $-3.64 | — |
| Q1 2025 | $1.3M | 39.0% | $-1.8M | $-1.7M | $-2.71 | — |
| Q4 2024 | $1.3M | 36.3% | $-2.0M | $-1.9M | $-4.35 | — |
| FY 2024 | $4.6M | 23.9% | $-8.1M | $-7.7M | $-27.55 | — |
| Q3 2024 | $1.2M | 24.7% | $-1.8M | $-1.7M | $-3.58 | — |
| Q2 2024 | $1.2M | 26.1% | $-1.7M | $-1.5M | $-3.71 | — |
| Q1 2024 | $901.9K | 2.4% | $0.00 | $-2.5M | $-15.24 | — |